Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | USP2 | O75604 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2700037 | 0.92 | CYP3A4 (0.49) | KDM4ECYP3A4TSHRCYP2C9CYP2C19 | |
| SCHEMBL2700036 | 0.92 | CYP3A4 (0.49) | KDM4ECYP3A4TSHRCYP2C9CYP2C19 | |
| SCHEMBL550240 | 0.89 | KDM4E (0.50) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL550595 | 0.88 | ALDH1A1 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL550388 | 0.81 | DDB1 (0.49) | KDM4ECYP3A4TSHRCYP2C19USP2 | |
| SCHEMBL550389 | 0.81 | DDB1 (0.49) | KDM4ECYP3A4TSHRCYP2C19USP2 | |
| SCHEMBL2700329 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL2700332 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL550908 | 0.79 | HSD11B1 (0.40) | ALDH1A1HSD11B1 | |
| SCHEMBL549294 | 0.79 | HSD11B1 (0.40) | ALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | claimed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | claimed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | claimed |
| EP-1812005-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-08-01 | — | — | EP | claimed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | claimed |
| WO-2006053024-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| EP-1812005-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | disclosed |
| WO-2006053024-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | KDM4E 3021/4885CYP3A4 219/4885TSHR 1512/4885 |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | KDM4E 3021/4885CYP3A4 219/4885TSHR 1512/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | KDM4E 3021/4885CYP3A4 219/4885TSHR 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.